Skip to main content
NCBI home page
Neuroscience Bulletin logoLink to Neuroscience Bulletin
. 2009 Oct 7;25(5):277–282. doi: 10.1007/s12264-009-0907-2

Neuroimaging study of placebo analgesia in humans

安慰剂镇痛的神经影像学研究

Yun-Hai Qiu 1,✉, Xin-Yin Wu 1, Hao Xu 1,2, David Sackett 3
PMCID: PMC5552608  PMID: 19784082

Abstract

Placebo has been reported to exert beneficial effects in patients regarding the treatment of pain. Human functional neuroimaging technology can study the intact human brain to elucidate its functional neuroanatomy and the neurobiological mechanism of the placebo effect. Blood flow measurement using functional magnetic resonance imaging and positron emission tomography (PET) has revealed that analgesia is related to decreased neural activities in pain-modulatory brain regions, such as the rostral anterior cingulate cortex (rACC), insula, thalamus, and brainstem including periaqueductal gray (PAG) and ventromedial medulla. The endogenous opioid system and its activation of μ-opioid receptors are thought to mediate the observed effects of placebo. The μ-opioid receptor-selective radiotracer-labeled PET studies show that the placebo effects are accompanied by reduction in activation of opioid neural transmission in pain-sensitive brain regions, including rACC, prefrontal cortex, insula, thalamus, amygdala, nucleus accumbens (NAC) and PAG. Further PET studies with dopamine D2/D3 receptor-labeling radiotracer demonstrate that basal ganglia including NAC are related to placebo analgesic responses. NAC dopamine release induced by placebo analgesia is related to expectation of analgesia. These data indicate that the aforementioned brain regions and neurotransmitters such as endogenous opioid and dopamine systems contribute to placebo analgesia.

Keywords: placebo, pain, functional magnetic resonance imaging, positron emission tomography, opioid, dopamine

References

  • [1].Hróbjartsson A., Gøtzsche P.C. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med. 2001;344:1594–1602. doi: 10.1056/NEJM200105243442106. [DOI] [PubMed] [Google Scholar]
  • [2].Hróbjartsson A., Gøtzsche P.C. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. J Intern Med. 2004;256:91–100. doi: 10.1111/j.1365-2796.2004.01355.x. [DOI] [PubMed] [Google Scholar]
  • [3].Wampold B.E., Minami T., Tierney S.C., Baskin T.W., Bhati K.S. The placebo is powerful: estimating placebo effects in medicine and psychotherapy from randomized clinical trials. J Clin Psychol. 2005;61:835–854. doi: 10.1002/jclp.20129. [DOI] [PubMed] [Google Scholar]
  • [4].Melzack R., Torgerson W.S. On the language of pain. Anesthesiology. 1971;34:50–59. doi: 10.1097/00000542-197101000-00017. [DOI] [PubMed] [Google Scholar]
  • [5].Vase L., Riley J.L., Price D.D. A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. Pain. 2002;99:443–452. doi: 10.1016/S0304-3959(02)00205-1. [DOI] [PubMed] [Google Scholar]
  • [6].Benedetti F., Mayberg H.S., Wager T.D., Stohler C.S., Zubieta J.K. Neurobiological mechanisms of the placebo effect. J Neurosci. 2005;25:10390–10402. doi: 10.1523/JNEUROSCI.3458-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [7].Price D.D., Finniss D.G., Benedetti F. A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol. 2008;59:565–590. doi: 10.1146/annurev.psych.59.113006.095941. [DOI] [PubMed] [Google Scholar]
  • [8].Zubieta J.K., Stohler C.S. Neurobiological mechanisms of placebo responses. Ann N Y Acad Sci. 2009;1156:198–210. doi: 10.1111/j.1749-6632.2009.04424.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [9].Wager T.D., Rilling J.K., Smith E.E., Sokolik A., Casey K.L., Davidson R.J., et al. Placebo-induced changes in FMRI in the anticipation and experience of pain. Science. 2004;303:1162–1167. doi: 10.1126/science.1093065. [DOI] [PubMed] [Google Scholar]
  • [10].Logothetis N.K., Pauls J., Augath M., Trinath T., Oeltermann A. Neurophysiological investigation of the basis of the fMRI signal. Nature. 2001;412:150–157. doi: 10.1038/35084005. [DOI] [PubMed] [Google Scholar]
  • [11].Bingel U., Lorenz J., Schoell E., Weiller C., Büchel C. Mechanisms of placebo analgesia: rACC recruitment of a subcortical antinociceptive network. Pain. 2006;120:8–15. doi: 10.1016/j.pain.2005.08.027. [DOI] [PubMed] [Google Scholar]
  • [12].Petrovic P., Kalso E., Petersson K.M., Ingvar M. Placebo and opioid analgesia-imaging a shared neuronal network. Science. 2002;295:1737–1740. doi: 10.1126/science.1067176. [DOI] [PubMed] [Google Scholar]
  • [13].Eippert F., Bingel U., Schoell E.D., Yacubian J., Klinger R., Lorenz J., et al. Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron. 2009;63:533–543. doi: 10.1016/j.neuron.2009.07.014. [DOI] [PubMed] [Google Scholar]
  • [14].Miller E.K., Cohen J.D. An integrative theory of prefrontal cortex function. Annu Rev Neurosci. 2001;24:167–202. doi: 10.1146/annurev.neuro.24.1.167. [DOI] [PubMed] [Google Scholar]
  • [15].Vogt B.A., Sikes R.W., Vogt L.J. Anterior cingulate cortex and the medial pain system. In: Gabriel M., editor. Neurobiology of cingulate cortex and limbic thalamus: a comprehensive handbook. Boston, MA: Birkhäuser; 1993. pp. 313–344. [Google Scholar]
  • [16].Fields H.L. Pain modulation: expectation, opioid analgesia and virtual pain. Prog Brain Res. 2000;122:245–253. doi: 10.1016/S0079-6123(08)62143-3. [DOI] [PubMed] [Google Scholar]
  • [17].Levine J.D., Gordon N.C., Fields H.L. The mechanism of placebo analgesia. Lancet. 1978;2:654–657. doi: 10.1016/S0140-6736(78)92762-9. [DOI] [PubMed] [Google Scholar]
  • [18].Gracely R.H., Dubner R., Wolskee P.J., Deeter W.R. Placebo and naloxone can alter post-surgical pain by separate mechanisms. Nature. 1983;306:264–265. doi: 10.1038/306264a0. [DOI] [PubMed] [Google Scholar]
  • [19].Grevert P., Albert L., Goldstein A. Partial antagonism of placebo analgesia by naloxone. Pain. 1983;16:129–143. doi: 10.1016/0304-3959(83)90203-8. [DOI] [PubMed] [Google Scholar]
  • [20].Levine J.D., Gordon N.C. Influence of the method of drug administration on analgesic response. Nature. 1984;312:755–756. doi: 10.1038/312755a0. [DOI] [PubMed] [Google Scholar]
  • [21].Benedetti F. The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain. 1996;64:535–543. doi: 10.1016/0304-3959(95)00179-4. [DOI] [PubMed] [Google Scholar]
  • [22].Zubieta J.K., Smith Y., Bueller J., Xu Y., Kilbourn M., Meyer C., et al. Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science. 2001;293:311–315. doi: 10.1126/science.1060952. [DOI] [PubMed] [Google Scholar]
  • [23].Zubieta J.K., Smith Y., Bueller J., Xu Y., Woike T., Kilbourn M., et al. μ-Opioid receptor mediated antinociception differs in men and women. J Neurosci. 2002;22:5100–5107. doi: 10.1523/JNEUROSCI.22-12-05100.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [24].Zubieta J.K., Heitzeg M.M., Smith Y.R., Bueller J.A., Xu K., Xu Y., et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 2003;299:1240–1243. doi: 10.1126/science.1078546. [DOI] [PubMed] [Google Scholar]
  • [25].Wager T.D., Scott D.J., Zubieta J.K. Placebo effects on human muopioid activity during pain. Proc Natl Acad Sci U S A. 2007;104:11056–11061. doi: 10.1073/pnas.0702413104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [26].Zubieta J.K., Bueller J.A., Jackson L.R., Scott D.J., Xu Y., Koeppe R.A., et al. Placebo effects mediated by endogenous opioid activity on m-opioid receptors. J Neurosci. 2005;25:7754–7762. doi: 10.1523/JNEUROSCI.0439-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [27].Scott D.J., Stohler C.S., Egnatuk C.M., Wang H., Koeppe R.A., Zubieta J.K. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry. 2008;65:220–231. doi: 10.1001/archgenpsychiatry.2007.34. [DOI] [PubMed] [Google Scholar]
  • [28].Vase L., Robinson M.E., Verne G.N., Price D.D. Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms. Pain. 2005;115:338–347. doi: 10.1016/j.pain.2005.03.014. [DOI] [PubMed] [Google Scholar]
  • [29].de la Fuente-Fernández R., Ruth T.J., Sossi V., Schulzer M., Calne D.B., Stoessl A.J. Expectation and dopamine release: mechanism of the placebo effect in Parkinson’s disease. Science. 2001;293:1164–1166. doi: 10.1126/science.1060937. [DOI] [PubMed] [Google Scholar]
  • [30].de la Fuente-Fernández R., Phillips A.G., Zamburlini M., Sossi V., Calne D.B., Ruth T.J., et al. Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res. 2002;136:359–363. doi: 10.1016/S0166-4328(02)00130-4. [DOI] [PubMed] [Google Scholar]
  • [31].Scott D.J., Stohler C.S., Egnatuk C.M., Wang H., Koeppe R.A., Zubieta J.K. Individual differences in reward responding explain placebo-induced expectations and effects. Neuron. 2007;55:325–336. doi: 10.1016/j.neuron.2007.06.028. [DOI] [PubMed] [Google Scholar]

Articles from Neuroscience Bulletin are provided here courtesy of Springer

RESOURCES